AstraZeneca coronavirus vaccine clinical trials resume in U.K. after pause over safety concerns
The United Kingdom’s Medicines Health Regulatory Authority that it was safe to resume clinical trials after a brief pause.
AstraZeneca paused trials earlier this week due to a potentially unexplained illness.
CEO Pascal Soriot said during a private conference call that the illness occurred in a woman in the U.K. who displayed neurological symptoms consistent with a spinal inflammatory disorder called transverse myelitis.
Illnesses often occur by chance in large trials but are investigated out of an abundance of caution.